Submit an IdeaBuilder Sign In
AGI Futures
AGI Futures
HealthcareBiotechSecurityExistential Risk MitigationResilienceEnder PreventionExistential Risk ReductionDifferentially Defensive

Pandemic 100-Day Countermeasure Platform

We proved we can design vaccines fast, but we cannot reliably go from novel pathogen to globally available countermeasures in a predictable time box.

Priority88
Importance95
Neglected70
Tractability55

The Gap

What exists is heroic, bespoke mobilization after the fire starts, with slow trials, fragile manufacturing, and politicized distribution. What could exist is a standing platform that makes “100 days to authorized vaccine, diagnostics, and first-line therapeutics” a default operating capability, not a miracle.

The Stakes

Pandemics are an extreme-cost tail risk that arrives more often than our institutions admit. The right framing is not just lives saved. It is global output preserved, trust preserved, and geopolitical instability avoided. Speed is compounding: every week matters because spread is exponential.

Headline evidence

  • •The IMF estimated cumulative global economic loss through 2024 from COVID-19 at about $13.8 trillion. [1]
  • •CEPI’s 100 Days Mission targets a new vaccine ready for initial authorization and manufacturing at scale within 100 days of identifying a new pandemic threat. [2]
  • •The Global Preparedness Monitoring Board argues epidemics and pandemics are now a “constant danger” rather than rare events. [3]

Neglectedness

InevitableNeglected

Why it stays neglected

    “Preparedness” has weak buyers. Budgets spike during crises and decay after. Manufacturing capacity is geographically concentrated and not easily repurposed. Regulatory, clinical trial, and procurement pipelines are not designed for parallelization. Global coordination fails exactly when nationalism rises.

Tractability

    Medium. The science of rapid design is proven. The blockers are execution infrastructure: adaptive trials, manufacturing tech transfer, regulatory playbooks, and distribution logistics. AI accelerates candidate design, protocol writing, pharmacovigilance, and manufacturing QA, but you still need metal, people, and agreements.

Startup surfaces

  • •Platformized adaptive trial networks with pre-approved protocols and standing sites
  • Manufacturing “plug compatibility” standards:tech transfer in weeks, not quarters
  • •Cold-chain and last-mile reliability tooling for low-resource settings
  • Regulatory-grade evidence automation:protocols, monitoring, audit trails, real-world safety
  • •Procurement and financing mechanisms that keep surge capacity alive between crises
Source Stack (5)
  • [1] WHO investment case citing IMF estimate of pandemic loss to 2024. (who.int )
  • [2] CEPI. The 100 Days Mission (program page). (cepi.net )
  • [3] Global Preparedness Monitoring Board. The Changing Face of Pandemic Risk (2024 report PDF). (gpmb.org )
  • [4] WHO and World Bank. Analysis of Pandemic Preparedness and Response financing needs and gaps (G20). (thedocs.worldbank.org )
  • [5] Barnsley G et al. Impact of the 100 Days Mission for vaccines on COVID-19. (2024). (thelancet.com )

Builder Proof-of-Work

Community submitted artifacts, notes, and implementations for this idea.

One AGI-era startup idea, every week.

Deep, open-sourced theses with scores, forecasts and the case for why now. Free.